Eli Lilly also filed lawsuits against compounding pharmacies and medical spas. Pharmaceutical company Eli Lilly warning in an open letter on Thursday about the dangers of fake and compounded ...

Eli Lilly LLY3.50%increase; green up pointing triangle is stepping up its campaign against fake and counterfeit weight-loss drugs with more lawsuits against sellers of unapproved products that ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

Eli Lilly (NYSE:LLY) and its rival weight loss drugmaker Novo Nordisk continue to battle compounders even as the FDA has declared that LLY’s popular GLP-1 drug, tirzepatide, marketed as Zepbound ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.

Eli Lilly is announcing a new way to get its popular Zepbound drug. People who are in need of weight loss medications but do not have insurance coverage will soon have a new way to access one of ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...